Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care

VAUGHAN, Ontario, & MENLO PARK, Calif.--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the creation of Orphia™, a new AI-powered digital health platform built on the belief that eye care providers should spend less time managing disconnected tools and technologies and more time caring for patients. The platform is brand agnostic and designed to serve all eye care providers, regardless of the products, devices or treatments they choose to use.

Orphia will operate under Digital Health Services, a newly created platform at Bausch + Lomb.

The first application of the Orphia digital health platform focuses on pre-surgery cataract education, helping patients understand their condition and treatment options, identifying concerns and preparing them before they meet with their surgeon. The goal is not simply to answer questions. It is to ensure patients arrive informed and ready, so conversations with their surgeon are more meaningful, allowing physicians to focus on what matters most: achieving the best possible outcome for each patient's vision.

To assist with the development of conversational patient engagement capability, Bausch + Lomb has engaged Hippocratic AI, a leader in voice AI agents for healthcare and life sciences, with a proprietary LLM built on more than 200 million real patient interactions, validated by more 7500 U.S.-licensed clinicians, and a track record of deployment across major health systems and health care organizations nationwide.

“We've invested deeply in developing better products, better molecules and better devices, and that work has advanced patient care. But one question has remained largely unanswered: How can we help physicians spend less time on everything around care and more time delivering it?” said Brent Saunders, Chairman and CEO, Bausch + Lomb. “Orphia was created to serve every eye care provider, no matter what they prescribe or what product they use.”

Orphia is designed to integrate with the systems that practices already use, complementing existing workflows and creating actionable insights for clinical teams. Over time, Bausch + Lomb plans to expand the platform’s capabilities to support the full patient journey, from care coordination to practice workflow, reducing the operational burden that stands between physicians and their patients.

Vance Thompson, MD, founder of Vance Thompson Vision and one of the world's leading cataract and refractive surgeons, said, “For decades, our teams have invested tremendous time educating patients before surgery because informed patients are more confident, more engaged and better prepared to make decisions about their vision. What excites me about this technology is that it allows our teams to focus their energy where it creates the greatest value: empathy, trust and personal connection. AI can handle many of the routine operational tasks like pre-op calls. People remain at the heart of care.”

The engagement of Hippocratic AI brings together Bausch + Lomb's deep understanding of eye care with a technology platform already trusted by many of the world's leading health care organizations, with the goal of creating solutions that support physicians, empower staff and help patients better understand their health care decisions.

“By embedding AI agents into daily workflows and providing the industry with an AI system that understands ophthalmology’s unique care models, we believe we can return valuable hours to physicians and their patients,” said Munjal Shah, CEO and co-founder, Hippocratic AI. “This is what abundance in health care looks like: freeing up health care professionals to always work at the top of their license.”

The Orphia digital health platform will be led by Manisha Narasimhan, PhD, president, Digital Health Services, Bausch + Lomb. Over the past three years, she has helped shape the company's strategy, AI and digital capabilities, positioning Bausch + Lomb to expand beyond traditional products into software-enabled eye care solutions. Narasimhan brings nearly two decades of experience spanning biotechnology, strategy, corporate development and digital transformation.

About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

About Hippocratic AI
Hippocratic AI is a native generative AI company on a mission to address the global shortage of clinicians and deliver healthcare abundance. A global leader and pioneer in safety-focused generative AI agents for healthcare through building a patented safety constellation architecture, Polaris, enabling non-diagnostic AI agents to support patients through natural conversations across a range of use cases, including care navigation, follow-ups, chronic disease management, education, preventative care, and much more across the patient and member continuum.

Forward-Looking Statements
This news release may contain forward-looking information and statements within the meaning of applicable securities laws (collectively, “forward-looking statements”). Forward-looking statements may generally be identified by the use of the words “anticipates,” “seeks,” “expects,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “potential,” “pending” or “proposed” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.